SLC25A42 promotes the growth of gastric cancer (GC) cells while suppresses ferroptosis by reprograming lipid metabolism through elevating the acetylation and thus expression of CPT2, implying that SLC25A42 could serve as a potential therapeutic strategy for the treatment of this malignancy. This evidence concerns the gene CPT2 and gastric cancer.